The discovery of anti-podocyte antibodies in primary membranous nephropathy (MN) has revolutionized our approach toward the diagnosis and treatment of this disease. Evaluation of serum levels of anti-podocyte antibodies paved the way for non-invasive diagnosis and helped distinguish between primary and secondary MN although the relationship between anti-podocyte antibodies and cancer remains to be elucidated. Serum levels of anti-PLA2R antibodies directed against the major podocyte autoantigen are related to MN activity and the decrease in serum levels of anti-PLA2R antibodies in response to treatment (immunologic remission) also serves as an early indicator of the later putative proteinuric remission, enabling personalization of the treatment. The serum levels of anti-podocyte antibodies also enable the prediction of renal outcomes in terms of both remission and the risk of progression to end-stage renal disease. The positivity of anti-PLA2R antibodies before renal transplantation is associated with the risk of recurrence of MN. It remains to be established if all these relations observed in patients with anti-PLA2R antibodies are also valid for expanding spectrum of antibodies directed against recently discovered minor antigens (e.g., THSD7A, NELL-1, semaphorin 3B).

Department of Nephrology 1st Faculty of Medicine General University Hospital Charles University Prague Czechia

Zobrazit více v PubMed

Ponticelli C, Glassock RJ. Glomerular diseases: membranous nephropathy – a modern view. Clin J Am Soc Nephrol. (2014) 9:609–16. 10.2215/CJN.04160413 PubMed DOI PMC

Glassock RJ. Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy. A new personalized medical approach. Clin J Am Soc Nephrol. (2014) 9:1341–3. 10.2215/CJN.05880614 PubMed DOI PMC

Donadio JV, Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, et al. . Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. (1988) 33:708–15. 10.1038/ki.1988.56 PubMed DOI

Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol. (1997) 8:664–74. PubMed

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al. . Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. (2019) 95:268–80. 10.1016/j.kint.2018.10.018 PubMed DOI

Cravedi P, Jarque M, Angeletti A, Fava A, Cantarelli C, Bestard O. Immune-monitoring diseaseactivity in primary membranous nephropathy. Front Med. (2019) 6:241. 10.3389/fmed.2019.00241 PubMed DOI PMC

Davison AM, Cameron IS, Kerr DN, Ogg CS, Wilkinson RW. The natural history of renal function in untreated membranous glomerulonephritis in adults. Clin Nephrol. (1984) 22:61–7. PubMed

Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. (1995) 25:862–75. 10.1016/0272-6386(95)90568-5 PubMed DOI

KDIGO clinical practice guideline for the treatment of glomerulonephritis . Kidney Int Supplements. (2012) 2:1–143. 10.1038/kisup.2012.9 DOI

Heymann W, Hackel DB, Harwood S, Wilson SGF, Hunter JLP. Production of the nephrotic syndrome in rats by Freund' s adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med. (1959) 100:660–4. 10.3181/00379727-100-24736 PubMed DOI

Sugisaki T, Klassen J, Andres GA, Milgrom F, McCluskey RT. Passive transfer of Heymann nephritis with serum. Kidney Int. (1973) 3:66–73. 10.1038/ki.1973.13 PubMed DOI

Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic comples: megalin (gp330) and RAP. J Am Soc Nephrol. (1995) 6:35–47. PubMed

Larsen CP, Trivin-Avillach C, Coles P, Collins AB, Merchant M, Ma H, et al. . LDL Receptor-related protein 2 (Megalin) as a target antigen in human kidney anti-brush border antibody disease. J Am Soc Nephrol. (2018) 29:644–53. 10.1681/ASN.2017060664 PubMed DOI PMC

Perez-Gomez MV, Sanchez-Nino MD, Ortiz A. Megalin/lipoprotein receptor-related protein 2 autoimmunity and kidney disease. Clin Kidney J. (2020) 13:281–6. 10.1093/ckj/sfz171 PubMed DOI PMC

Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T, et al. . Role of truncating mutations in MME gene in fetomaternal alloimunisation and antenatal glomerulopathies. Lancet. (2004) 364:1252–9. 10.1016/S0140-6736(04)17142-0 PubMed DOI

Beck LH, Jr, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. (2009) 361:11–21. 10.1056/NEJMoa0810457 PubMed DOI PMC

Tomas NM, Beck LH, Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. . Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. (2014) 371:2277–87. 10.1056/NEJMoa1409354 PubMed DOI PMC

Sethi S, Debiec H, Madden B, Charlesworth MC, Morelle J, Gross LA, et al. . Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. (2020) 97:162–74. 10.1016/j.kint.2019.09.014 PubMed DOI

Sethi S, Debiec H, Madden B, Vivarelli M, Charlesworth MC, Ravindran A, et al. . Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. (2020) 98:1253–64. 10.1016/j.kint.2020.05.030 PubMed DOI

Kudose S, Santoriello D, Debiec H, Canetta PA, Bomback AS, Stokes MB, et al. . The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney Int. (2021) 99:247–55. 10.1016/j.kint.2020.06.014 PubMed DOI

Sethi S, Madden BJ, Gross L, Negron VC, Charlesworth C, Debiec H, et al. . Protocadherin 7-Associated Membranous Nephropathy. Abstract FR-OR36. ASN; (2020). PubMed PMC

Al-Rabadi L, Caza T, Avillach C, Rodan AR, Williams B, Abraham J, et al. . High Temperature Recombinant Protein A1 (HTRA1): A Novel Antigen in Membranous Nephropathy. Abstract FR-OR35. ASN; (2020).

Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross LA, Ravindran A, et al. . Exostosin 1/exostosin 2 – associated membranous nephropathy. J Am Soc Nephrol. (2019) 30:1123–36. 10.1681/ASN.2018080852 PubMed DOI PMC

Caza T, Hassen S, Kuperman MB, Sharma S, Dvanajscak Z, Arthur J, et al. . Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int. (2020). 10.1016/j.kint.2020.09.016. [Epub ahead of print]. PubMed DOI PMC

Ravindran A, Moura MC, Fervenza FC, Nasr SH, Alexander MP, Fidler ME, et al. . In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes. J Am Soc Nephrol. (2021) 32:695–706. 10.1681/ASN.2020081181 PubMed DOI PMC

Sethi S. New ‘antigens' in membranous nephropathy. J Am Soc Nephrol. (2020) 32:268–78. 10.1681/ASN.2020071082 PubMed DOI PMC

Ahmad SB, Appel G. Antigens, antibodies, and membranous nephropathy: a decade of progress. Kidney Int. (2020) 97:29–31. 10.1016/j.kint.2019.10.009 PubMed DOI

Larsen CP, Cossey LN, Beck LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol. (2016) 29:421–6. 10.1038/modpathol.2016.32 PubMed DOI PMC

Wang J, Cui Z, Lu J, Probst C, Zhang Y–M, Wang X, et al. . Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol. (2017) 12:1642–51. 10.2215/CJN.01460217 PubMed DOI PMC

Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payre C, Jourd-Chiche N, et al. . Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. (2019) 95:666–79. 10.1016/j.kint.2018.10.024 PubMed DOI

Tominaga K, Uchida T, Imakiire T, Itoh K, Shimazaki H, Nakanishi K, et al. . Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phosphlipase A2 receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis. BMC Nephrol. (2018) 19:120. 10.1186/s12882-018-0922-5 PubMed DOI PMC

Alawieh R, Brodsky SV, Satoskar AA, Nadasdy T, Parikh SV, Rovin B, Cassol C. Membranous nephropathy with crescents. Kidney Int Rep. (2020) 5:537–41. 10.1016/j.ekir.2020.01.010 PubMed DOI PMC

Nikolopoulou A, Huang-Doran I, McAdoo SP, Griffith ME, Cook HT, Pusey CD. Membranous nephropathy with crescents. Kidney Int Rep. (2019 4:1577–84. PubMed PMC

Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. (2011) 364:689–90. 10.1056/NEJMc1011678 PubMed DOI

Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrespective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. (2013) 28:1839–44. 10.1093/ndt/gfs439 PubMed DOI

Van de Loght A-E, Hofstra JM, Wetzels JFM. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int. (2015) 87:1263–4. 10.1038/ki.2015.34 PubMed DOI

Ramachandran R, Kumar V, Nada R, Jha V. Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. Kidney Int. (2015) 88:1198–9. 10.1038/ki.2015.310 PubMed DOI

Ryan MS, Satoskar AA, Nadasdy GM, Brodsky SV, Hemminger JA, Nadasdy T. Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis. Kidney Int. (2016) 89:1402–3. 10.1016/j.kint.2015.12.057 PubMed DOI

Lin L, Wang WM, Pan XX, Xu J, Gao CN, Zhang W, et al. . Biomarkers to detect membranous nephropathy in Chinese patients. Oncotarget. (2016) 7:67868–79. 10.18632/oncotarget.12014 PubMed DOI PMC

Couser WG. The pathogenesis of human membranous nephropathy: we are almost there. Kidney Int. (2020) 97:849–52. 10.1016/j.kint.2020.01.037 PubMed DOI

Ravindran A, Madden B, Charlesworth MC, Sharma R, Sethi A, Debiec H, et al. . Proteomic analysis of complement proteins in membranous nephropathy. Kidney Int Rep. (2020) 5:618–26. 10.1016/j.ekir.2020.01.018 PubMed DOI PMC

Brglez V, Boyer-Suavet S, Seitz-Polski B. Complement pathways in membranous nephropathy: complex and multifactorial. Kidney Int Rep. (2020) 5:572–4. 10.1016/j.ekir.2020.02.1033 PubMed DOI PMC

Tomas NM, Hoxha E, Reinicke AT, Fester L, Helmchen U, Gerth J, et al. . Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest. (2016) 126:2519–32. 10.1172/JCI85265 PubMed DOI PMC

Tomas NM, Meyer-Schwesinger C, von Spiegel H, Kotb AM, Zahner G, Hoxha E, et al. . A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. J Am Soc Nephrol. (2017) 28:3262–77. 10.1681/ASN.2017010030 PubMed DOI PMC

Meyer-Schwesinger C, Tomas NM, Dehde S, Seifert L, Hermans-Borgmeyer I, Wiech T, et al. . A novel mouse model of phospholipase A2 receptor 1 associated membranous nephropathy. Clin J Am Soc Nephrol. (2017) 12:983–97. 10.1016/j.kint.2019.10.022 PubMed DOI

Cornaby C, Gibbons L, Mayhew V, Sloan CS, Welling A, Poole BD. B cell epitope spreading: mechanisms and contribution to autoimmune diseases. Immunol Lett. (2015) 163:56–68. 10.1016/j.imlet.2014.11.001 PubMed DOI

Seitz-Polski B, Dolla G, Payré C, Girard CA, Polidori J, Zorzi K, et al. . Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol. (2016) 27:1517–33. 10.1681/ASN.2014111061 PubMed DOI PMC

Stanescu HC, Arco-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al. . Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy. N Engl J Med. (2011) 364:616–26. 10.1056/NEJMoa1009742 PubMed DOI

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. . Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. (2012) 367:214–23. 10.1056/NEJMoa1108735 PubMed DOI PMC

Lv J, Hou W, Zhou X, Liu G, Zhou F, Zhao N, et al. . Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol. (2013) 24:1323–9. 10.1681/ASN.2012080771 PubMed DOI PMC

Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, et al. . Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. (2013) 83:940–8. 10.1038/ki.2012.486 PubMed DOI

Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al. . The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun. (2020) 11:1600. 10.1038/s41467-020-15383-w PubMed DOI PMC

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, et al. . Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. (2012) 8:e1002765. 10.1371/journal.pgen.1002765 PubMed DOI PMC

Bobart SA, Fervenza FC. Kidney biopsy is required for nephrotic syndrome with PLA2R+ and normal kidney function: the CON view. Kidney360. (2020) 1:890–3. 10.34067/KID.0003262020 PubMed DOI PMC

Hogan JJ. Kidney biopsy is required for nephrotic syndrome with PLA2R+ and normal kidney function: PRO. Kidney360. (2020) 1:887–9. 10.34067/KID.0003752020 PubMed DOI PMC

Burbelo PD, Joshi M, Chaturvedi A, Little DJ, Thurlow JS, Waldman M, et al. . Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. J Am Soc Nephrol. (2020) 31:308–17. 10.1681/ASN.2019050538 PubMed DOI PMC

Wang Q, Dong ZZ, Zhang WG, Liu XM, Qu YL, Duan SW, et al. . Diagnostic efficacy of serum anti-phospholipase A2 receptor antibodies for idiopathic membranous nephropathy in patients with diabetic kidney disease. Clin Chim Acta. (2020) 502:222–6. 10.1016/j.cca.2019.11.004 PubMed DOI

De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. (2017) 28:421–30. 10.1681/ASN.2016070776 PubMed DOI PMC

Leeaphorn N, Kue-A-Pai P, Thamcharoen N, Ungprasert P, Stoke MB, Knight EL. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. (2014) 40:29–35. 10.1159/000364782 PubMed DOI

Hoxha E, Wiech T, Stahl PR, Zahner G, Tomas NM, Meyer-Schwesinger C, et al. . A mechanism for cancer-associated membranous nephropathy. N Engl J Med. (2016) 374:1995–6. 10.1056/NEJMc1511702 PubMed DOI

Pozdzik A, Brochériou I, David C, Touzani F, Goujon JM, Wissing KM. Membranous nephropathy and anti-podocytes antibodies: Implications for the diagnostic workup and disease management. Biomed Res Int. (2018) 2018:6281054. 10.1155/2018/6281054 PubMed DOI PMC

Zhang C, Zhang M, Chen D, Ren Q, Xu W, Zeng C, et al. . Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy. Clin Pathol. (2019) 72:705–11. 10.1136/jclinpath-2019-205852 PubMed DOI

Radice A, Pieruzzi F, Trezzi B, Ghiggeri G, Napodano P, D'Amico M, et al. . Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. J Nephrol. (2018) 31:271–8. 10.1007/s40620-017-0451-5 PubMed DOI

Von Haxthausen F, Reinhard L, Pinnschmidt HO, Rink M, Soave A, Hoxha E, et al. . Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy. Front Immunol. (2018) 9:3035. 10.3389/fimmu.2018.03035 PubMed DOI PMC

Caza T, Hassen S, Dvanajscak Z, Kuperman M, Edmondson R, Herzog C, et al. . NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. (2020) 10.1016/j.kint.2020.07.039. [Epub ahead of print]. PubMed DOI PMC

Zhang D, Zhang C, Bian F, Zhang W, Jiang G, Zou J. Clinicopathological features in membranous nephropathy with cancer: a retrospective single-center study and literature review. Int J Biol Markers. (2019) 34:406–13. 10.1177/1724600819882698 PubMed DOI

Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, et al. . Antiphospholipase A2 receptor antibody titre and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. (2012) 23:1735–43. 10.1681/ASN.2012030242 PubMed DOI PMC

Hofstra JM, Beck LH, Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. (2011) 6:1286–91. 10.2215/CJN.07210810 PubMed DOI PMC

Jullien P, Seitz-Polski B, Maillard N, Thibaudin D, Laurent B, Ollier E, et al. . Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy. Clin Kidney J. (2017) 10:209–14. 10.1093/ckj/sfw121 PubMed DOI PMC

Timmermans S, Abdul Hamid MA, Cohen Tervaert JW, Damoiseaux J, van Paassen P. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am J Nephrol. (2014) 142:29–34. 10.1159/000437236 PubMed DOI

Rodas LM, Matas-Garcia A, Barrox X, Blasco M, Vinas O, Llobell A, et al. . Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J. (2019) 12:36–41. 10.1093/ckj/sfy005 PubMed DOI PMC

Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RAK. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. (2014) 25:1357–66. 10.1681/ASN.2013040430 PubMed DOI PMC

Seitz-Polski B, Debiec H, Rousseau A, Dahan K, Zaghrini C, Payré C, et al. . Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced lilkelihood of remission in membranous nephropathy. J Am Soc Nephrol. (2018) 29:401–8. 10.1681/ASN.2017070734 PubMed DOI PMC

Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int. (2017) 91:304–14. 10.1016/j.kint.2016.08.030 PubMed DOI

Passerini P, Malvica S, Tripodi F, Cerutti R, Messa P. Membranous nephropathy (MN) recurrence after renal transplantation. Front Immunol. (2019) 10:1326. 10.3389/fimmu.2019.01326 PubMed DOI PMC

Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med. (2010) 363:496–8. 10.1056/NEJMc1003066 PubMed DOI

Quintana LF, Blasco M, Seras M, Pérez NS, López-Hoyos M, Villarroel P, et al. . Antiphospholipase A2 receptor antibocy levels predict the risk of posttransplantation recurrence of membranous nephropathy. Transplantation. (2015) 99:1709–14. 10.1097/TP.0000000000000630 PubMed DOI

Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, et al. . Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropath post-kidney transplantation. Clin Transplant. (2016) 30:461–9. 10.1111/ctr.12711 PubMed DOI

Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RAK. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. (2014) 9:1883–90. 10.2215/CJN.03850414 PubMed DOI PMC

Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, et al. . Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. (2015) 26:2545–58. 10.1681/ASN.2014070640 PubMed DOI PMC

Beck LH, Jr, Fervenza FC, Beck DM, Bonegion GB, Malik FA, Erickson SB, et al. . Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. (2011) 22:1543–50. 10.1681/ASN.2010111125 PubMed DOI PMC

Qin W, Beck LH, Jr, Zeng C, Chen Z, Li S, Zuo K, et al. . Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. (2011) 22:1137–43. 10.1681/ASN.2010090967 PubMed DOI PMC

Ramachandran R, Yadav AK, Kumar V, Inamdar N, Nada R, Gupta KL, et al. . Temporal association between PLA2R antibodies and clinical outcomes in primary membranous nephropathy. Kidney Int Rep. (2018) 3:142–7. 10.1016/j.ekir.2017.09.001 PubMed DOI PMC

Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al. . Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. (2017) 28:348–58. 10.1681/ASN.2016040449 PubMed DOI PMC

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. . Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. (2019) 381:36–46. 10.1056/NEJMoa1814427 PubMed DOI

Fernández-Juárez G, Rojas-Rivera J, van de Logt AE, Justino J, Sevillano A, Caravaca-Fontán F, et al. . The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. (2020). 10.1016/j.kint.2020.10.014. [Epub ahead of print]. PubMed DOI

Barrett C, Willcocks LC, Jones RB, Tarzi RM, Henderson RB, Cai G, et al. . Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant. (2020) 35:599–606. 10.1093/ndt/gfz086 PubMed DOI PMC

Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, et al. . High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol. (2019) 14:1173–82. 10.2215/CJN.11791018 PubMed DOI PMC